JP2024073654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024073654A5 JP2024073654A5 JP2024047652A JP2024047652A JP2024073654A5 JP 2024073654 A5 JP2024073654 A5 JP 2024073654A5 JP 2024047652 A JP2024047652 A JP 2024047652A JP 2024047652 A JP2024047652 A JP 2024047652A JP 2024073654 A5 JP2024073654 A5 JP 2024073654A5
- Authority
- JP
- Japan
- Prior art keywords
- expression cassette
- cells
- integrated
- vector
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 16
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 15
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 11
- 210000005155 neural progenitor cell Anatomy 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 8
- 230000001939 inductive effect Effects 0.000 claims 8
- 239000004098 Tetracycline Substances 0.000 claims 7
- 230000002457 bidirectional effect Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 229960002180 tetracycline Drugs 0.000 claims 7
- 229930101283 tetracycline Natural products 0.000 claims 7
- 235000019364 tetracycline Nutrition 0.000 claims 7
- 150000003522 tetracyclines Chemical class 0.000 claims 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 5
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 5
- 108091027981 Response element Proteins 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 239000003900 neurotrophic factor Substances 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 4
- 241000702421 Dependoparvovirus Species 0.000 claims 4
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000006801 homologous recombination Effects 0.000 claims 4
- 238000002744 homologous recombination Methods 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229960003722 doxycycline Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000003061 neural cell Anatomy 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 210000001353 entorhinal cortex Anatomy 0.000 claims 1
- 210000001320 hippocampus Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000000337 motor cortex Anatomy 0.000 claims 1
- 230000006548 oncogenic transformation Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644332P | 2018-03-16 | 2018-03-16 | |
| US62/644,332 | 2018-03-16 | ||
| US201862773752P | 2018-11-30 | 2018-11-30 | |
| US62/773,752 | 2018-11-30 | ||
| JP2020549702A JP7535944B2 (ja) | 2018-03-16 | 2019-03-15 | 神経栄養因子の誘導可能な発現のための方法及び組成物 |
| PCT/US2019/022595 WO2019178550A1 (en) | 2018-03-16 | 2019-03-15 | Methods and compositions for inducible expression of neurotrophic factors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549702A Division JP7535944B2 (ja) | 2018-03-16 | 2019-03-15 | 神経栄養因子の誘導可能な発現のための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024073654A JP2024073654A (ja) | 2024-05-29 |
| JP2024073654A5 true JP2024073654A5 (https=) | 2025-02-14 |
Family
ID=67907321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549702A Active JP7535944B2 (ja) | 2018-03-16 | 2019-03-15 | 神経栄養因子の誘導可能な発現のための方法及び組成物 |
| JP2024047652A Pending JP2024073654A (ja) | 2018-03-16 | 2024-03-25 | 神経栄養因子の誘導可能な発現のための方法及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549702A Active JP7535944B2 (ja) | 2018-03-16 | 2019-03-15 | 神経栄養因子の誘導可能な発現のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12258571B2 (https=) |
| EP (1) | EP3765058A4 (https=) |
| JP (2) | JP7535944B2 (https=) |
| KR (1) | KR102843346B1 (https=) |
| CN (1) | CN111867617A (https=) |
| AU (1) | AU2019236288B2 (https=) |
| WO (1) | WO2019178550A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190018000A1 (en) | 2016-01-12 | 2019-01-17 | Cedars-Sinai Medical Center | A method of non destructive monitoring of biological processes in microfluidic tissue culture systems |
| CA3012042A1 (en) | 2016-01-26 | 2017-08-03 | Cedars-Sinai Medical Center | Systems and methods for in vivo dual recombinase-mediated cassette exchange (drmce) and disease models thereof |
| WO2018140647A1 (en) | 2017-01-25 | 2018-08-02 | Cedars-Sinai Medical Center | In vitro induction of mammary-like differentiation from human pluripotent stem cells |
| US11767513B2 (en) | 2017-03-14 | 2023-09-26 | Cedars-Sinai Medical Center | Neuromuscular junction |
| US11414648B2 (en) | 2017-03-24 | 2022-08-16 | Cedars-Sinai Medical Center | Methods and compositions for production of fallopian tube epithelium |
| US12258571B2 (en) | 2018-03-16 | 2025-03-25 | Cedars-Sinai Medical Center | Methods and compositions for inducible expression of neurotrophic factors |
| EP4700387A2 (en) | 2018-03-23 | 2026-02-25 | Cedars-Sinai Medical Center | Methods of use of islet cells |
| EP3775161A4 (en) | 2018-04-06 | 2022-04-06 | Cedars-Sinai Medical Center | NEURODEGENERATIVE DISEASE MODELS DERIVED FROM HUMAN PLURIPOTENTIC STEM CELLS ON A MICROFLUIDIC CHIP |
| US11981918B2 (en) | 2018-04-06 | 2024-05-14 | Cedars-Sinai Medical Center | Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells |
| EP3787613B1 (en) | 2018-04-30 | 2026-03-11 | Cedars-Sinai Medical Center | Pkc activation for use in treating early onset sporadic parkinson's disease |
| WO2020084168A1 (en) * | 2018-10-26 | 2020-04-30 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Tetracycline compound for treating drug-induced dyskinesia |
| AU2020370288B2 (en) * | 2019-10-22 | 2026-02-12 | Cedars-Sinai Medical Center | Cortical neural progenitor cells from iPSCs |
| US20230047254A1 (en) * | 2019-12-29 | 2023-02-16 | Gloriana Therapeutics | Mammalian Cells Secreting GDNF and Their Therapeutic Use |
| KR20220061403A (ko) * | 2020-11-06 | 2022-05-13 | (주) 에스바이오메딕스 | 다능성 줄기세포 유래 신경전구세포를 포함하는 퇴행성 뇌질환 치료용 약학적 조성물 |
| CN121420065A (zh) * | 2023-06-29 | 2026-01-27 | 香港大学 | 用于在肝脏或肝癌中的可控转录的方法 |
| GB202312699D0 (en) * | 2023-08-18 | 2023-10-04 | Cambridge Entpr Ltd | Controllable expression in mammalian cells |
| WO2025091023A1 (en) * | 2023-10-27 | 2025-05-01 | Northwestern University | Engineered cell transfected by all-in-one vector for therapeutic agents production and delivery and applications thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US20030084468A1 (en) | 2001-09-05 | 2003-05-01 | Economides Aris N. | Methods of expressing transgenes |
| WO2003090689A2 (en) * | 2002-04-25 | 2003-11-06 | Wisconsin Alumni Research Foundation | Neurodegenerative disorder treatment using gdnf secreting neural cells |
| GB2404382B (en) | 2003-07-28 | 2008-01-30 | Oxitec Ltd | Pest control |
| US20120107284A1 (en) * | 2006-06-30 | 2012-05-03 | Elena Kozlova | Stem cells for transplantation and methods for production thereof |
| US20100077495A1 (en) | 2006-12-21 | 2010-03-25 | Davis David P | Compositions and methods for the expression of nucleic acids |
| US8592211B2 (en) * | 2009-03-20 | 2013-11-26 | The Rockefeller University | Enhanced PiggyBac transposon and methods for transposon mutagenesis |
| US20120107938A1 (en) | 2009-06-29 | 2012-05-03 | University Of Basel | Methods and kits for high efficiency engineering of conditional mouse alleles |
| WO2013155222A2 (en) * | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Brain-specific enhancers for cell-based therapy |
| CN102816793B (zh) * | 2012-08-22 | 2014-09-10 | 陕西师范大学 | 单载体双向启动的Tet-on诱导表达系统及其构建方法和应用 |
| JP2016508520A (ja) | 2013-02-15 | 2016-03-22 | インターナショナル ステム セル コーポレイション | 神経変性疾患の治療のための、ヒト多能性幹細胞に由来する神経細胞の使用 |
| US10519421B2 (en) | 2013-03-21 | 2019-12-31 | Kyoto University | Induction of motor neurons from pluripotent stem cells |
| WO2014204724A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| WO2015143342A1 (en) | 2014-03-21 | 2015-09-24 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
| CA2943296C (en) * | 2014-03-21 | 2022-10-18 | The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) | Stable gene transfer to proliferating cells |
| EP3122370A1 (en) | 2014-03-28 | 2017-02-01 | Buck Institute for Research on Aging | Methods and compositions for modulating the immune system |
| AU2015279552B2 (en) | 2014-06-27 | 2021-01-21 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3012042A1 (en) | 2016-01-26 | 2017-08-03 | Cedars-Sinai Medical Center | Systems and methods for in vivo dual recombinase-mediated cassette exchange (drmce) and disease models thereof |
| US10221395B2 (en) | 2016-06-16 | 2019-03-05 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
| US12258571B2 (en) | 2018-03-16 | 2025-03-25 | Cedars-Sinai Medical Center | Methods and compositions for inducible expression of neurotrophic factors |
| KR20220024527A (ko) | 2019-06-17 | 2022-03-03 | 세다르스-신나이 메디칼 센터 | 생체내 이중 재조합효소-매개된 카세트 교환 (dRMCE)을 위한 시스템 및 방법 그리고 이들의 질환 모델 |
-
2019
- 2019-03-15 US US16/979,640 patent/US12258571B2/en active Active
- 2019-03-15 JP JP2020549702A patent/JP7535944B2/ja active Active
- 2019-03-15 EP EP19768063.0A patent/EP3765058A4/en active Pending
- 2019-03-15 KR KR1020207029729A patent/KR102843346B1/ko active Active
- 2019-03-15 AU AU2019236288A patent/AU2019236288B2/en active Active
- 2019-03-15 CN CN201980019683.6A patent/CN111867617A/zh active Pending
- 2019-03-15 WO PCT/US2019/022595 patent/WO2019178550A1/en not_active Ceased
-
2024
- 2024-03-25 JP JP2024047652A patent/JP2024073654A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024073654A5 (https=) | ||
| JP2021518365A5 (https=) | ||
| Pang et al. | Neuroinflammation and scarring after spinal cord injury: therapeutic roles of MSCs on inflammation and glial scar | |
| O’Carroll et al. | AAV targeting of glial cell types in the central and peripheral nervous system and relevance to human gene therapy | |
| Park et al. | Human neural stem cells over-expressing choline acetyltransferase restore cognition in rat model of cognitive dysfunction | |
| Dirren et al. | SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice | |
| Sullivan et al. | Neurotrophic factors for the treatment of Parkinson's disease | |
| Cowansage et al. | Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity | |
| JPWO2019178550A5 (https=) | ||
| Domanskyi et al. | Prospects of neurotrophic factors for Parkinson's disease: comparison of protein and gene therapy | |
| Renaud-Gabardos et al. | Internal ribosome entry site-based vectors for combined gene therapy | |
| US20140234275A1 (en) | Method for treating als via the increased production of factor h | |
| WO2009052737A1 (en) | Medicament for preventing and controlling alzheimer's disease | |
| EP4442830A1 (en) | Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease | |
| US11872290B2 (en) | Bicistronic AAV vector for RNA interference in ALS | |
| Manfredsson et al. | Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease | |
| Stavrou et al. | Charcot–Marie–Tooth neuropathies: current gene therapy advances and the route toward translation | |
| Yurek et al. | Intracerebral injections of DNA nanoparticles encoding for a therapeutic gene provide partial neuroprotection in an animal model of neurodegeneration | |
| Zhu et al. | Neuroprotective effects of human umbilical cord-derived mesenchymal stem cells from different donors on spinal cord injury in mice | |
| JP2023500302A (ja) | Ｔｍｅｍ１７６ｂ、その発現または活性モジュレーターを有効成分として含む神経変性脳疾患の予防または治療用組成物 | |
| Wang et al. | TIP60 buffers acute stress response and depressive behaviour by controlling PPARγ-mediated transcription | |
| Zhou et al. | IL-23 priming enhances the neuroprotective effects of MSC-derived exosomes in treating retinal degeneration | |
| US10220077B2 (en) | Combination treatment for amyotrophic lateral sclerosis (ALS) | |
| EP2626419B1 (en) | Human neural stem cells expressing human choline acetyltransferase, and use thereof | |
| CA3179874A1 (en) | Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders |